Market Cap 67.47M
Revenue (ttm) 200,000.00
Net Income (ttm) -26.17M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -13,085.00%
Debt to Equity Ratio -0.25
Volume 50,300
Avg Vol 77,536
Day's Range N/A - N/A
Shares Out 12.78M
Stochastic %K 69%
Beta 0.96
Analysts Strong Sell
Price Target $32.00

Company Profile

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic...

Industry: Packaged Foods
Sector: Consumer Defensive
Phone: 801 676 9695
Website: clene.com
Address:
6550 South Millrock Drive, Suite G50, Salt Lake City, United States
Takeover24
Takeover24 Aug. 7 at 2:00 PM
$CLNN Let's also not forget the photo of Dan Tate attending the FDA rare disease meeting w/ I am ALS. Now we know Dan has been taking CNM-Au8 for over six years with what he describes as remarkable results, I would expect him to be a compelling voice at any AdCom, alongside other patients and clinicians such as Dr. Andrews. Given what we just saw with REPL, and when you combine that with the devastating nature of ALS, the limited treatment options currently available, the lack of any other near-term ALS therapies under FDA review, the excellent safety profile and ease of use, and the fact that it can be added to existing standard-of-care therapies rather than replace them, the odds seem to have shifted significantly in CLNN's favor. Yet the market has not adjusted to this vastly improving regulatory picture. But some day it will.
1 · Reply
simon1967
simon1967 Aug. 7 at 11:47 AM
$CLNN Here and there I check AI chat about Clene:" If CNM-Au8 demonstrates a meaningful survival benefit for ALS patients and annual sales eventually exceed $500 million, the market could value Clene at more than $2.X billion, which would justify a share price toward the upper end of the range $50-80 per share. "
2 · Reply
Takeover24
Takeover24 Aug. 7 at 5:53 AM
$CLNN I believe REPL's AA is a meaningful regulatory read-through for $CLNN. As FDA leadership recently told the rare disease community, the agency appears willing to exercise appropriate regulatory flexibility for serious diseases when the totality of the evidence supports approval. REPL is a good example—despite a challenging data package and FDA briefing documents that were highly critical before the AdCom. It's not a direct comparison, but I actually think CLNN's regulatory setup is stronger. FDA has already told the company it could proceed with an AA filing based on its existing data package following the Type C meeting, and CLNN's application is supported by prospectively planned analyses rather than relying primarily on post hoc findings. No guarantees, but today's decision makes me even more optimistic about CLNN's chances.
1 · Reply
prusio1
prusio1 Aug. 6 at 5:59 PM
$CLNN The selling overhang on CLNN may finally be coming to an end. Today's Form 4 wasn't a warrant sale. It reports that 375,000 $30 warrants and 424,358 $4.82 warrants are no longer beneficially owned by Ugwumba because SymBiosis II LLC transferred investment management to an unaffiliated third-party manager. As a result, Ugwumba no longer has voting or investment control over the fund's CLNN holdings. The filing explicitly states no warrants were sold, exercised, or transferred, and no consideration was paid. SymBiosis II LLC has been one of CLNN's largest institutional shareholders, and Ugwumba had been filing Form 4s as its managing partner while the fund gradually reduced its common stock position over the past several months. If most of that selling is now behind us, this could mark the end of a significant source of selling pressure.
1 · Reply
7m3835d3
7m3835d3 Aug. 6 at 2:29 PM
$CLNN 3% up on a 9k volume lol everyone is just waiting, we are so close. At least we don’t creep slowly down anymore
0 · Reply
paule815
paule815 Aug. 6 at 1:49 PM
$CLNN When I slide in, something happens. 😎 ooooooowheeeee. Haahaa. Tell me. You think NEXT THURSDAY will be nice? Or next next? If you want me to, I’ll send you a picture of the facility, it’s only 45 minutes away.
1 · Reply
kay91667
kay91667 Aug. 4 at 2:22 PM
$CLNN Empery Asset Management just filed a 13G reporting ownership of 916,532 shares (7.17%). Based on the recent financing price, that's roughly a $4.2 million investment. Empery is a well-known institutional investor that frequently participates in biotech financings. While this filing is likely related to the recent offering rather than open-market buying, it's still encouraging to see a sophisticated fund taking a meaningful equity position. Definitely worth keeping an eye on.
1 · Reply
Mulhollandr
Mulhollandr Aug. 4 at 12:52 AM
$CLNN now I know someone is messing with us. Up 8% AH with like 400 share volume. 😂
0 · Reply
fibonacci1170
fibonacci1170 Aug. 3 at 5:59 PM
$CLNN This is nothing short of a super-volcano rumbling to go off in the next ~7 months. Massive. The key hint that this is getting approved is that despite primary endpoint failure, the FDA saw that there is a survival signal, and encouraged Clene to go for AA. But AA can only be given for NfL reduction. So the FDA wants Clene to simply connect the NfL reduction to the survival signal. Once this paperwork is done (~Sept), the FDA can officially approve the drug. It is just about the paperwork from here on. That's my take.
1 · Reply
Lane0507
Lane0507 Aug. 3 at 3:31 PM
$CLNN Has limited treatment options. If CNM-Au8 demonstrates meaningful clinical benefit or gains accelerated approval. The commercial opportunity could be significant despite Clene's small size.
1 · Reply
Latest News on CLNN
Clene to Present at The Canaccord 46th Annual Growth Conference

Jul 29, 2026, 8:30 AM EDT - 11 days ago

Clene to Present at The Canaccord 46th Annual Growth Conference


Clene reports Q1 EPS (69c), consensus (70c)

2026-05-14T16:30:10.000Z - 3 months ago

Clene reports Q1 EPS (69c), consensus (70c)


Clene Quarterly report: Q1 2026

May 14, 2026, 7:00 AM EDT - 3 months ago

Clene Quarterly report: Q1 2026


Clene Earnings release: Q1 2026

May 14, 2026, 7:00 AM EDT - 3 months ago

Clene Earnings release: Q1 2026


Clene price target raised to $50 from $48 at Canaccord

2026-05-08T11:23:32.000Z - 3 months ago

Clene price target raised to $50 from $48 at Canaccord


Clene Transcript: Emerging Growth Conference 92

May 6, 2026, 3:25 PM EDT - 3 months ago

Clene Transcript: Emerging Growth Conference 92


Clene to Present at Upcoming May Conferences

May 5, 2026, 8:00 AM EDT - 3 months ago

Clene to Present at Upcoming May Conferences


Clene Proxy statement: Proxy filing

Apr 10, 2026, 8:00 AM EDT - 4 months ago

Clene Proxy statement: Proxy filing


Clene Proxy statement: Proxy filing

Apr 10, 2026, 8:00 AM EDT - 4 months ago

Clene Proxy statement: Proxy filing


Clene reports FY25 EPS ($2.65), consensus ($2.35)

2026-03-12T12:12:18.000Z - 5 months ago

Clene reports FY25 EPS ($2.65), consensus ($2.35)


Clene Annual report: Q4 2025

Mar 12, 2026, 8:00 AM EDT - 5 months ago

Clene Annual report: Q4 2025


Clene Annual report: Q4 2025

Mar 12, 2026, 8:00 AM EDT - 5 months ago

Clene Annual report: Q4 2025


Clene Earnings release: Q4 2025

Mar 12, 2026, 8:00 AM EDT - 5 months ago

Clene Earnings release: Q4 2025


Clene Transcript: Emerging Growth Virtual Conference

Feb 25, 2026, 1:45 PM EST - 5 months ago

Clene Transcript: Emerging Growth Virtual Conference


Clene issues letter to shareholders on CNM-Au8 2026 catalysts

2026-02-24T13:13:07.000Z - 5 months ago

Clene issues letter to shareholders on CNM-Au8 2026 catalysts


Clene to Present at the Emerging Growth Conference

Feb 19, 2026, 8:30 AM EST - 6 months ago

Clene to Present at the Emerging Growth Conference


Clene Transcript: Emerging Growth Conference 89

Jan 21, 2026, 3:10 PM EST - 7 months ago

Clene Transcript: Emerging Growth Conference 89


Clene announces over $28M registered direct offering

2026-01-09T13:41:01.000Z - 7 months ago

Clene announces over $28M registered direct offering


Clene Announces Registered Direct Offering of Over $28 Million

Jan 9, 2026, 8:30 AM EST - 7 months ago

Clene Announces Registered Direct Offering of Over $28 Million


Clene Transcript: Emerging Growth Conference 88

Dec 10, 2025, 4:25 PM EST - 8 months ago

Clene Transcript: Emerging Growth Conference 88


Clene price target raised to $30 from $20 at Maxim

2025-12-03T18:15:36.000Z - 8 months ago

Clene price target raised to $30 from $20 at Maxim


Clene Transcript: Study Update

Dec 3, 2025, 8:30 AM EST - 8 months ago

Clene Transcript: Study Update


Clene Press release: Study Update

Dec 3, 2025, 8:30 AM EST - 8 months ago

Clene Press release: Study Update


Clene Slides: Study Update

Dec 3, 2025, 8:30 AM EST - 8 months ago

Clene Slides: Study Update


Clene to Provide CNM-Au8® ALS Program Update

Dec 2, 2025, 5:39 PM EST - 8 months ago

Clene to Provide CNM-Au8® ALS Program Update


Clene reports Q3 EPS (85c), consensus (56c)

2025-11-13T13:10:28.000Z - 9 months ago

Clene reports Q3 EPS (85c), consensus (56c)


Clene sees cash runway into 2Q26

2025-11-13T13:10:16.000Z - 9 months ago

Clene sees cash runway into 2Q26


Clene Earnings release: Q3 2025

Nov 13, 2025, 8:00 AM EST - 9 months ago

Clene Earnings release: Q3 2025


Clene Quarterly report: Q3 2025

Nov 13, 2025, 8:00 AM EST - 9 months ago

Clene Quarterly report: Q3 2025


Clene Transcript: Emerging Growth Conference

Oct 23, 2025, 3:10 PM EDT - 10 months ago

Clene Transcript: Emerging Growth Conference


Clene announces presentation of combined REPAIR-MS results

2025-09-25T12:10:32.000Z - 11 months ago

Clene announces presentation of combined REPAIR-MS results


Clene price target lowered to $31 from $33 at Benchmark

2025-09-10T12:00:43.000Z - 11 months ago

Clene price target lowered to $31 from $33 at Benchmark


Clene Registration statement: Registration Filing

Sep 5, 2025, 8:00 AM EDT - 1 year ago

Clene Registration statement: Registration Filing


Clene Transcript: Emerging Growth Conference 85

Aug 20, 2025, 2:20 PM EDT - 1 year ago

Clene Transcript: Emerging Growth Conference 85


Clene price target lowered to $48 from $83 at Canaccord

2025-08-18T10:40:11.000Z - 1 year ago

Clene price target lowered to $48 from $83 at Canaccord


Clene reports Q2 EPS (78c) vs ($1.06) last year

2025-08-14T12:45:43.000Z - 1 year ago

Clene reports Q2 EPS (78c) vs ($1.06) last year


Clene Earnings release: Q2 2025

Aug 14, 2025, 8:30 AM EDT - 1 year ago

Clene Earnings release: Q2 2025


Clene Quarterly report: Q2 2025

Aug 14, 2025, 8:30 AM EDT - 1 year ago

Clene Quarterly report: Q2 2025


Clene Transcript: Emerging Growth Conference 84

Jul 17, 2025, 3:10 PM EDT - 1 year ago

Clene Transcript: Emerging Growth Conference 84


Clene Transcript: Q2 Virtual Investor Summit Event

Jun 10, 2025, 1:00 PM EDT - 1 year ago

Clene Transcript: Q2 Virtual Investor Summit Event


Clene Transcript: Emerging Growth Conference 82

May 21, 2025, 3:10 PM EDT - 1 year ago

Clene Transcript: Emerging Growth Conference 82


Clene Slides: Investor Presentation

May 14, 2025, 7:00 AM EDT - 1 year ago

Clene Slides: Investor Presentation


Clene Earnings release: Q1 2025

May 7, 2025, 8:00 AM EDT - 1 year ago

Clene Earnings release: Q1 2025


Clene Quarterly report: Q1 2025

May 7, 2025, 8:00 AM EDT - 1 year ago

Clene Quarterly report: Q1 2025


Clene Proxy statement: Proxy Filing

Apr 8, 2025, 8:00 AM EDT - 1 year ago

Clene Proxy statement: Proxy Filing


Clene Proxy statement: Proxy Filing

Apr 8, 2025, 8:00 AM EDT - 1 year ago

Clene Proxy statement: Proxy Filing


Clene Proxy statement: Proxy Filing

Mar 28, 2025, 8:00 AM EDT - 1 year ago

Clene Proxy statement: Proxy Filing


Clene Annual report: Q4 2024

Mar 24, 2025, 9:00 AM EDT - 1 year ago

Clene Annual report: Q4 2024


Clene Earnings release: Q4 2024

Mar 24, 2025, 9:00 AM EDT - 1 year ago

Clene Earnings release: Q4 2024


Clene Registration statement: Registration Filing

Mar 24, 2025, 8:00 AM EDT - 1 year ago

Clene Registration statement: Registration Filing


Clene Transcript: 37th Annual ROTH Conference

Mar 18, 2025, 12:30 PM EDT - 1 year ago

Clene Transcript: 37th Annual ROTH Conference


Clene to Present at the 37TH Annual Roth Conference

Mar 6, 2025, 8:30 AM EST - 1 year ago

Clene to Present at the 37TH Annual Roth Conference


Clene Registration statement: Registration Filing

Jan 24, 2025, 7:00 AM EST - 1 year ago

Clene Registration statement: Registration Filing


Clene Slides: Investor Presentation

Dec 10, 2024, 7:00 AM EST - 1 year ago

Clene Slides: Investor Presentation


Clene Quarterly report: Q3 2024

Nov 13, 2024, 7:00 AM EST - 1 year ago

Clene Quarterly report: Q3 2024


Clene Earnings release: Q3 2024

Nov 13, 2024, 7:00 AM EST - 1 year ago

Clene Earnings release: Q3 2024


Clene Registration statement: Registration Filing

Nov 13, 2024, 7:00 AM EST - 1 year ago

Clene Registration statement: Registration Filing


Clene Quarterly report: Q2 2024

Aug 7, 2024, 7:00 AM EDT - 2 years ago

Clene Quarterly report: Q2 2024


Clene Earnings release: Q2 2024

Aug 7, 2024, 7:00 AM EDT - 2 years ago

Clene Earnings release: Q2 2024


Clene Announces 1-for-20 Reverse Stock Split

Jul 9, 2024, 8:00 AM EDT - 2 years ago

Clene Announces 1-for-20 Reverse Stock Split


Clene Quarterly report: Q1 2024

May 8, 2024, 7:00 AM EDT - 2 years ago

Clene Quarterly report: Q1 2024


Clene Earnings release: Q1 2024

May 8, 2024, 7:00 AM EDT - 2 years ago

Clene Earnings release: Q1 2024


Clene Proxy statement: Proxy Filing

Apr 16, 2024, 8:00 AM EDT - 2 years ago

Clene Proxy statement: Proxy Filing


Clene Proxy statement: Proxy Filing

Apr 16, 2024, 8:00 AM EDT - 2 years ago

Clene Proxy statement: Proxy Filing


Clene Proxy statement: Proxy Filing

Apr 5, 2024, 8:00 AM EDT - 2 years ago

Clene Proxy statement: Proxy Filing


Clene Annual report: Q4 2023

Mar 13, 2024, 8:00 AM EDT - 2 years ago

Clene Annual report: Q4 2023


Clene Earnings release: Q4 2023

Mar 13, 2024, 8:00 AM EDT - 2 years ago

Clene Earnings release: Q4 2023


Takeover24
Takeover24 Aug. 7 at 2:00 PM
$CLNN Let's also not forget the photo of Dan Tate attending the FDA rare disease meeting w/ I am ALS. Now we know Dan has been taking CNM-Au8 for over six years with what he describes as remarkable results, I would expect him to be a compelling voice at any AdCom, alongside other patients and clinicians such as Dr. Andrews. Given what we just saw with REPL, and when you combine that with the devastating nature of ALS, the limited treatment options currently available, the lack of any other near-term ALS therapies under FDA review, the excellent safety profile and ease of use, and the fact that it can be added to existing standard-of-care therapies rather than replace them, the odds seem to have shifted significantly in CLNN's favor. Yet the market has not adjusted to this vastly improving regulatory picture. But some day it will.
1 · Reply
simon1967
simon1967 Aug. 7 at 11:47 AM
$CLNN Here and there I check AI chat about Clene:" If CNM-Au8 demonstrates a meaningful survival benefit for ALS patients and annual sales eventually exceed $500 million, the market could value Clene at more than $2.X billion, which would justify a share price toward the upper end of the range $50-80 per share. "
2 · Reply
Takeover24
Takeover24 Aug. 7 at 5:53 AM
$CLNN I believe REPL's AA is a meaningful regulatory read-through for $CLNN. As FDA leadership recently told the rare disease community, the agency appears willing to exercise appropriate regulatory flexibility for serious diseases when the totality of the evidence supports approval. REPL is a good example—despite a challenging data package and FDA briefing documents that were highly critical before the AdCom. It's not a direct comparison, but I actually think CLNN's regulatory setup is stronger. FDA has already told the company it could proceed with an AA filing based on its existing data package following the Type C meeting, and CLNN's application is supported by prospectively planned analyses rather than relying primarily on post hoc findings. No guarantees, but today's decision makes me even more optimistic about CLNN's chances.
1 · Reply
prusio1
prusio1 Aug. 6 at 5:59 PM
$CLNN The selling overhang on CLNN may finally be coming to an end. Today's Form 4 wasn't a warrant sale. It reports that 375,000 $30 warrants and 424,358 $4.82 warrants are no longer beneficially owned by Ugwumba because SymBiosis II LLC transferred investment management to an unaffiliated third-party manager. As a result, Ugwumba no longer has voting or investment control over the fund's CLNN holdings. The filing explicitly states no warrants were sold, exercised, or transferred, and no consideration was paid. SymBiosis II LLC has been one of CLNN's largest institutional shareholders, and Ugwumba had been filing Form 4s as its managing partner while the fund gradually reduced its common stock position over the past several months. If most of that selling is now behind us, this could mark the end of a significant source of selling pressure.
1 · Reply
7m3835d3
7m3835d3 Aug. 6 at 2:29 PM
$CLNN 3% up on a 9k volume lol everyone is just waiting, we are so close. At least we don’t creep slowly down anymore
0 · Reply
paule815
paule815 Aug. 6 at 1:49 PM
$CLNN When I slide in, something happens. 😎 ooooooowheeeee. Haahaa. Tell me. You think NEXT THURSDAY will be nice? Or next next? If you want me to, I’ll send you a picture of the facility, it’s only 45 minutes away.
1 · Reply
kay91667
kay91667 Aug. 4 at 2:22 PM
$CLNN Empery Asset Management just filed a 13G reporting ownership of 916,532 shares (7.17%). Based on the recent financing price, that's roughly a $4.2 million investment. Empery is a well-known institutional investor that frequently participates in biotech financings. While this filing is likely related to the recent offering rather than open-market buying, it's still encouraging to see a sophisticated fund taking a meaningful equity position. Definitely worth keeping an eye on.
1 · Reply
Mulhollandr
Mulhollandr Aug. 4 at 12:52 AM
$CLNN now I know someone is messing with us. Up 8% AH with like 400 share volume. 😂
0 · Reply
fibonacci1170
fibonacci1170 Aug. 3 at 5:59 PM
$CLNN This is nothing short of a super-volcano rumbling to go off in the next ~7 months. Massive. The key hint that this is getting approved is that despite primary endpoint failure, the FDA saw that there is a survival signal, and encouraged Clene to go for AA. But AA can only be given for NfL reduction. So the FDA wants Clene to simply connect the NfL reduction to the survival signal. Once this paperwork is done (~Sept), the FDA can officially approve the drug. It is just about the paperwork from here on. That's my take.
1 · Reply
Lane0507
Lane0507 Aug. 3 at 3:31 PM
$CLNN Has limited treatment options. If CNM-Au8 demonstrates meaningful clinical benefit or gains accelerated approval. The commercial opportunity could be significant despite Clene's small size.
1 · Reply
Woodman7
Woodman7 Aug. 3 at 11:34 AM
$CLNN From @Takeover24 ’s post this weekend:
1 · Reply
Takeover24
Takeover24 Aug. 2 at 11:31 PM
$CLNN I AM ALS just posted the following on their socials and this may be an absolute game changer: "I am living proof of the power of the medicine and the innovation. I have been on a therapy for almost six years that gave me back my voice. Before I entered an Expanded Access Program through ACT for ALS, I needed an amplifier to be understood. I haven't used one in almost six years. Everything in ACT for ALS was novel from the beginning. Before it, there was nothing available to any of us. Now we all have hope"—Dan Tate, Jr. They are almost certainly referring to CNM-Au8 as I found this article about him where he says the same thing and specifically references CNM-Au8: "Dan taking his first dose of CNM-Au8, an amazing therapy he credits for giving him back his voice. Prior to going on it in early December, his voice was very weak, requiring him to use an amp and microphone. Since starting CNM-Au8, he hasn’t needed them." https://sssasmagazine.org/when-the-game-changes/ (con't)
1 · Reply
paule815
paule815 Aug. 1 at 11:27 AM
$CLNN Stay alert! It’s August and I’m feeling something.
0 · Reply
7m3835d3
7m3835d3 Jul. 31 at 12:50 PM
$CLNN one day closer. I think they will announce NDA submission in the next 1-2 weeks, possibly before the Aug 11 conference. More likely before the Aug 19 conference
2 · Reply
Takeover24
Takeover24 Jul. 31 at 12:00 AM
$CLNN I asked Claude to provide a summary of the recent CAPR and REPL adcoms and any read through for CLNN. Here is what it spit out: $CLNN — the CAPR/REPL adcomm split, and why it matters for our ALS accelerated approval thesis This week gave us a rare natural experiment: two adcomms, same FDA committee (CTGTAC), back to back, opposite outcomes. Worth unpacking in full because the read-through to $CLNN is more specific than "biotech sentiment good/bad." $CAPR — voted down 9-3 (Wed 7/29) Deramiocel for DMD cardiomyopathy. This wasn't a case of thin data getting punished — patient and family testimony was described as "moving," and the panel even found some encouraging signal in upper-limb function data. What sank it: FDA's briefing docs argued the efficacy claims leaned on a statistical analysis plan that looked assembled after the company saw favorable results, not one locked in advance.
1 · Reply
paule815
paule815 Jul. 30 at 6:37 PM
$CLNN mid August I will make one last increase. Then, I’ll just sit back at a distance.
1 · Reply
goldenegg1
goldenegg1 Jul. 30 at 1:06 PM
$CLNN Overall market sentiment is positive today, yet CLNN is being pinned lower by unusually large sell orders in a stock that normally trades very light volume. Whether its intention is to discourage buyers, creating the appearance of heavy supply or an algorithm, one thing is clear: low liquidity makes it easier to influence the price. The investment thesis hasn't changed. CLNN is working toward its NDA submission, and many investors remain encouraged by the FDA's constructive feedback during prior interactions. If the company continues to execute on that path, today's premarket price action may prove to be just short-term noise. Good luck to all the long-term holders.
1 · Reply
GenX420
GenX420 Jul. 30 at 11:18 AM
$CLNN How low can it go?
3 · Reply
goldenegg1
goldenegg1 Jul. 29 at 10:53 PM
$CLNN think you're underestimating CLNN's management. This isn't a first-time biotech team learning the FDA process. They have decades of experience in drug development, regulatory affairs, clinical development, and commercialization. I'm sure they're watching every high-profile FDA decision, including CAPR's AdCom, and incorporating those lessons into their own strategy. Any competent biotech preparing a BLA would do exactly that. Yes, the FDA expects rigorous statistics, a prespecified SAP, and clear justification for every analysis. That's nothing new. Those are exactly the issues experienced management teams spend months preparing for and discussing with the FDA. At the end of the day, approval will come down to the quality of the data—not the assumption that management is walking into the BLA unprepared.
0 · Reply
fibonacci1170
fibonacci1170 Jul. 29 at 10:06 PM
$CLNN I hope CLENE management watch CAPR adcom and prepare the BLA accordingly. Leave no room for ambiguity about SAP modifications, data imputation, statistical analysis, etc ... If any doubts, then clarify with the FDA first. Don't just assume that the FDA will be okay with your approach. Because the FDA will destroy CLENE otherwise. FDA is a slave of p-values and bureaucratic procedures. It doesn't care about pain and suffering. I hope CLENE understands what is at stake and is not taking things for granted.
1 · Reply
Chris150
Chris150 Jul. 29 at 3:56 PM
$CLNN Clene Inc. will present at Emerging Growth Conference 95 - August 19 & 20 with CEO Rob Etherington and CFO Morgan Brown. https://x.com/EmergingGrowthC/status/2082486582552977531
1 · Reply
Mulhollandr
Mulhollandr Jul. 29 at 3:23 PM
$CLNN annoyed but nothing has changed regarding the long term thesis.
0 · Reply